
|Videos|October 26, 2022
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
Author(s)Urology Times staff
Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Advertisement
Rana McKay, MD, discusses the evolving treatment paradigm in the second-line setting for advanced renal cell carcinoma now that immunotherapy has revolutionized the first-line approach. McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5









